Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
The current study is a phase II multi-center single arm trial to evaluate the efficacy and
safety of inductive Anti-PD-1+P-GEMOX treatment followed by radiotherapy and concurrent
Anti-PD-1 antibody in early-stage high-risk extranodal NK/T cell lymphoma, nasal type
Phase:
Phase 2
Details
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborators:
Beijing Cancer Hospital First Affiliated Hospital of Jilin University The Affiliated Hospital Of Guizhou Medical University